In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies

@article{Chatalic2016InVS,
  title={In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies},
  author={Kristell L.S. Chatalic and Mark W. Konijnenberg and Julie Nonnekens and Erik de Blois and Sander Hoeben and Corrina M. A. de Ridder and Luc Brunel and Jean-Alain Fehrentz and Jean Martinez and Dik C. van Gent and Berthold A. Nock and Theodosia Maina and Wytske M. van Weerden and Marion de Jong},
  journal={Theranostics},
  year={2016},
  volume={6},
  pages={104 - 117}
}
A single tool for early detection, accurate staging, and personalized treatment of prostate cancer (PCa) would be a major breakthrough in the field of PCa. Gastrin-releasing peptide receptor (GRPR) targeting peptides are promising probes for a theranostic approach for PCa overexpressing GRPR. However, the successful application of small peptides in a theranostic approach is often hampered by their fast in vivo degradation by proteolytic enzymes, such as neutral endopeptidase (NEP). Here we show… 
Metabolically Stabilized (68)Ga-NOTA-Bombesin for PET Imaging of Prostate Cancer and Influence of Protease Inhibitor Phosphoramidon.
TLDR
The recently proposed "serve-and-protect" strategy may not be valid for peptides exhibiting favorable intrinsic metabolic stability in vivo, as evaluated a novel (68)Ga-labeled bombesin derivative for PET imaging of prostate cancer in vivo.
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
TLDR
The findings indicate that 68Ga- or 177Lu-labeled NeoBOMB1 is a promising radiotracer with excellent tumor uptake and favorable pharmacokinetics for imaging and therapy of GRPR-expressing tumors.
Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results
TLDR
The GRPR antagonist radioligands 67Ga-, 111In-, and 177Lu-NeoBOMB1, independent of the radiometal applied, have shown comparable behavior in prostate cancer models, in favor of future theranostic use in GRPR-positive cancer patients.
In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer
TLDR
Co-administration of PA increased in vivo tumor targeting capacity of Sarabesin 3, making this an attractive combination for GRPR-targeted tumor imaging.
Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
TLDR
It is shown that amide-to-triazole substitutions in 177Lu-DOTA-PEG4-[Nle14]BBN(7-14) induced minor effects on bioavailability and tumor uptake in mice models, whereas in-situ NEP-inhibition by PA impressively improved in vivo profiles.
New Frontiers in Molecular Imaging Using Peptide-Based Radiopharmaceuticals for Prostate Cancer
TLDR
The preclinical and clinical literature in the past 20 years is reviewed and the newer developments of peptide-based radiopharmaceuticals for the imaging and therapy of PCa are focused on.
A novel peptide targeting gastrin releasing peptide receptor for pancreatic neoplasm detection.
TLDR
A novel six-amino acid peptide, GB-6, which maintains a specific GRPR-binding feature and exhibits enhanced stability in vitro and in vivo, was designed and proven to be a more promising candidate for the clinical diagnosis of pancreatic cancer.
In Vivo Biodistribution and Efficacy Evaluation of NeoB, A Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor
TLDR
NeoB is a radiotracer targeting the gastrin-releasing peptide receptor (GRPR), a G-protein–coupled receptor expressed in various cancers, and exhibited excellent pharmacokinetics with elevated and prolonged tumor uptake and low uptake in non-target organs such as pancreas.
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe
TLDR
This study suggests that the peptide A9 represents a good lead candidate for development of molecular probe, to be used for imaging purposes and for the delivery of cytotoxic agents.
[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes
TLDR
The attractive pharmacokinetic profile of [99mTc]DB15 in mice and its capability to target GRPR-positive BC lesions in patients highlight its prospects for a broader clinical use, an option currently being explored by ongoing clinical studies.
...
1
2
3
4
...

References

SHOWING 1-10 OF 53 REFERENCES
Targeted Radiotherapy of Prostate Cancer with a Gastrin-Releasing Peptide Receptor Antagonist Is Effective as Monotherapy and in Combination with Rapamycin
TLDR
Radiotherapy using a 177Lu-labeled GRPr antagonist alone or in combination with rapamycin was efficacious in inhibiting in vivo tumor growth and may be a promising strategy for treatment of prostate cancer.
In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer
TLDR
Targeting GRP-R–expressing BC tumors using GRp-R radioligands is promising for nuclear imaging and therapy, especially in ER-positive BC patients.
177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.
TLDR
177Lu-AMBA binds with nanomolar affinity to GRP-R and NMB-R, has low retention of radioactivity in kidney, demonstrates a very favorable risk-benefit profile, and is in phase I clinical trials.
In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
TLDR
Coadministration of both lysine and PA with [(177)Lu]DOTA-GRP(13-27) appeared to induce a clear improvement of tumor uptake as well as lower levels of renal radioactivity, causing a promising ninefold increase in tumor/kidney ratios.
Preclinical Comparison of Al18F- and 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer
TLDR
GRPR specificity was confirmed by significantly reduced tumor uptake of the 3 tracers after coinjection of a 100-fold excess of unlabeled JMV4168 or JMV5132, and tracer biodistribution was determined by ex vivo measurements.
In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548
TLDR
BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer and has a sensitivity, specificity, and accuracy of 88, 81, and 83%, respectively, for detection of primary PCa and sensitivity for metastatic lymph nodes using histology as gold standard.
“To Serve and Protect”: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting
TLDR
The results of this study clearly demonstrate that the coadministration of key enzyme inhibitors can effectively prolong the survival of radiolabeled peptides in the circulation, securing their safe transit to the target.
Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
TLDR
There are strong arguments indicating that sst2 antagonists may be worth testing in vivo in patients in a wide range of tumors including nonneuroendocrine tumors.
Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.
TLDR
High GRP receptor density was only observed in androgen-dependent PC xenografts, indicating highGRP receptor expression in the early, androgenous, stages of prostate tumor development and not in later stages, and suggests that GRP receptors may be used as new visualization and treatment modalities for these tumors.
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
TLDR
Five clinical studies performed in subjects with metastatic castration-resistant prostate cancer using 177Lu-J591 showed the potential therapeutic value of radioimmunotherapy (RIT) in metastatic PCa, and 177Lu imaging studies demonstrated accurate targeting of known metastatic sites.
...
1
2
3
4
5
...